- Home
- GOAI vs CNTB Comparison
GOAI vs CNTB Comparison
Compare GOAI & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GOAI | CNTB |
|---|---|---|
| Founded | 2015 | 2012 |
| Country | United States | United States |
| Employees | 3 | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 118.7M | 135.7M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | GOAI | CNTB |
|---|---|---|
| Price | $2.48 | $2.12 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.67 |
| AVG Volume (30 Days) | 121.5K | ★ 203.0K |
| Earning Date | 04-10-2026 | 08-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $64,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $18.31 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.07 | $0.91 |
| 52 Week High | $6.67 | $3.82 |
Technical Indicators
Market Signals| Indicator | GOAI | CNTB |
|---|---|---|
| Relative Strength Index (RSI) | 34.40 | 39.96 |
| Support Level | N/A | $2.03 |
| Resistance Level | $4.36 | $2.68 |
| Average True Range (ATR) | 0.45 | 0.19 |
| MACD | -0.07 | -0.01 |
| Stochastic Oscillator | 18.42 | 8.33 |
Price Performance
Historical ComparisonAbout GOAI Eva Live Inc. Common Stock
Eva Live Inc is a United States-based technology company that has developed an automated and intelligent advertiser campaign management platform, Eva Platform, which enables advertisers ('customers, clients') to buy advertising space on several digital channels to reach their desired audience. The company also works with Businesses that utilize its in-house digital marketing capabilities, including advice, creative services, account management, production of advertising materials, media planning, and buying.
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.